Ranibizumab biosimilar - BIOCND

Drug Profile

Ranibizumab biosimilar - BIOCND

Alternative Names: BCD-300

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator BIOCND
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Macular degeneration

Most Recent Events

  • 16 Dec 2016 Preclinical trials in Macular degeneration in South Korea (unspecified route) before December 2016
  • 16 Dec 2016 BIOCND files an IND application in South Korea for Macular degeneration before December 2016 (BIOCND pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top